Literature DB >> 1382801

Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease.

W R Gibb1.   

Abstract

The anatomy of melanin-containing neurons and other midbrain structures was examined by tyrosine hydroxylase (TH), calbindin D28k, and substance P immunostaining. Greater than 95% of cells in the substantia nigra pars compacta contained melanin, but densely packed cells in a ventral tier had a low content of melanin and loosely packed cells in a dorsal tier had a high content of melanin. Approximately 60% in the gamma group and 40% in the retrorubral nucleus had a low content of melanin. TH immunostaining was moderate in both the ventral and dorsal tiers, but more intense in the gamma group and retrorubral nucleus. Calbindin D28k was absent from the ventral and dorsal tiers, but present in the gamma group and retrorubral nucleus. In the light of primate tracing studies these findings suggest that the ventral tier of the pars compacta projects to striosomes of the striatum and the dorsal tier, gamma group and retrorubral nucleus to the matrix compartment. The ventral tier is more vulnerable than the dorsal tier in Parkinson's disease, but the cells contain less melanin. Neither tier contains calbindin D28k. This differential vulnerability between the ventral and dorsal tiers cannot be explained by melanin or calbindin D28k.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382801     DOI: 10.1016/0006-8993(92)90719-p

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  37 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

2.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface.

Authors:  William D Bush; Jacob Garguilo; Fabio A Zucca; Alberto Albertini; Luigi Zecca; Glenn S Edwards; Robert J Nemanich; John D Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 4.  Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.

Authors:  Rainer Knörle
Journal:  Neurotox Res       Date:  2017-09-06       Impact factor: 3.911

Review 5.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.

Authors:  L Zecca; D Tampellini; M Gerlach; P Riederer; R G Fariello; D Sulzer
Journal:  Mol Pathol       Date:  2001-12

Review 6.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

7.  X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues.

Authors:  A J Kropf; B A Bunker; M Eisner; S C Moss; L Zecca; A Stroppolo; P R Crippa
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

8.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

9.  Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.

Authors:  Vivek Lawana; Se Young Um; Jean-Christophe Rochet; Robert J Turesky; Jonathan H Shannahan; Jason R Cannon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

10.  Dual effects of TNFalpha on nerve fiber formation from ventral mesencephalic organotypic tissue cultures.

Authors:  Franziska Marschinke; Ingrid Strömberg
Journal:  Brain Res       Date:  2008-04-09       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.